Emerging strategies for the clinical application of rapamycin
- 1 July 1998
- journal article
- review article
- Published by Elsevier in Clinical Biochemistry
- Vol. 31 (5) , 341-344
- https://doi.org/10.1016/s0009-9120(98)00044-7
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- THE SYNERGISTIC EFFECTS OF CYCLOSPORINE AND SIROLIMUSTransplantation, 1997
- EFFECTS OF THE PHARMACOKINETIC INTERACTION BETWEEN ORALLY ADMINISTERED SIROLIMUS AND CYCLOSPORINE ON THE SYNERGISTIC PROLONGATION OF HEART ALLOGRAFT SURVIVAL IN RATS1Transplantation, 1996
- Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506Kidney International, 1996
- SYNERGISTIC EFFECTS OF CYCLOSPORINE AND RAPAMYCIN IN A CHRONIC NEPHROTOXICITY MODEL1Transplantation, 1996
- The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone-treated renal transplant patientsKidney International, 1996
- Control of p70 S6 kinase by kinase activity of FRAP in vivoNature, 1995
- SYNERGISTIC INTERACTIONS OF CYCLOSPORINE AND RAPAMYCIN TO INHIBIT IMMUNE PERFORMANCES OF NORMAL HUMAN PERIPHERAL BLOOD LYMPHOCYTES IN VITROTransplantation, 1991
- CyclosporineNew England Journal of Medicine, 1989
- Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.The Journal of Antibiotics, 1975
- BIOCHEMICAL BACKGROUND OF TRIMETHOPRIM/SULPHAMETHOXAZOLEThe Medical Journal of Australia, 1973